CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
First Claim
1. A cysteine engineered anti-MUC16 antibody which binds to a MUC16 polypeptide and comprising one or more free cysteine amino acids and a sequence selected from SEQ ID NOS:
- 9-40.
1 Assignment
0 Petitions
Accused Products
Abstract
Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I:
Ab-(L-D)p I
where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
-
Citations
57 Claims
- 1. A cysteine engineered anti-MUC16 antibody which binds to a MUC16 polypeptide and comprising one or more free cysteine amino acids and a sequence selected from SEQ ID NOS:
-
17. A method of determining the presence of a MUC16 protein in a sample suspected of containing said protein, said method comprising the steps of:
-
exposing said sample to a cysteine engineered anti-MUC16 antibody having one or more free cysteine amino acids and a sequence selected from SEQ ID NOS;
9-40, and;determining binding of said antibody to said MUC16 protein in said sample, wherein binding of the antibody to said protein is indicative of the presence of said protein in said sample. - View Dependent Claims (18, 19)
-
-
21. A pharmaceutical formulation comprising a cysteine engineered anti-MUC16 antibody which binds to a MUC16 polypeptide and comprising one or more free cysteine amino acids and a sequence selected from SEQ ID NOS:
- 9-40, and a pharmaceutically acceptable diluent, carrier or excipient.
-
22. An antibody-drug conjugate comprising a cysteine engineered anti-MUC16 antibody (Ab) which binds to a MUC16 polypeptide and comprising one or more free cysteine amino acids, a sequence selected from SEQ ID NOS:
- 9-40, and an auristatin drug moiety (D) wherein the cysteine engineered anti-MUC16 antibody is attached through one or more free cysteine amino acids by a linker moiety (L) to D;
the compound having Formula I;
Ab-(L-D)p
Iwhere p is 1, 2, 3, or 4. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
- 9-40, and an auristatin drug moiety (D) wherein the cysteine engineered anti-MUC16 antibody is attached through one or more free cysteine amino acids by a linker moiety (L) to D;
-
26. The antibody-drug conjugate compound of claim 24 wherein Ww is valine-citrulline.
-
27. The antibody-drug conjugate compound of claim 24 wherein R17 is (CH2)5 or (CH2)2.
-
28. The antibody-drug conjugate compound of claim 24 having the formula:
-
29. The antibody-drug conjugate compound of claim 28 wherein R17 is (CH2)5 or (CH2)2.
-
30. The antibody-drug conjugate compound of claim 24 having the formula:
-
31. The antibody drug conjugate of claim 22 wherein L is MC-val-cit-PAB or MC.
-
32. The antibody-drug conjugate compound of claim 22 wherein L is a linker formed by linker reagents SMCC, BM(PEO)2 or BM(PEO)3.
-
33. The antibody-drug conjugate compound of claim 22 wherein D is MMAE, having the structure:
-
34. The antibody-drug conjugate compound of claim 22 wherein D is MMAF, having the structure:
-
35. The antibody-drug conjugate compound of claim 22 wherein the cysteine engineered anti-MUC16 antibody is selected from a monoclonal antibody, a bispecific antibody, a chimeric antibody, a human antibody, and a humanized antibody.
-
36. The antibody-drug conjugate compound of claim 22 wherein the cysteine engineered anti-MUC16 antibody is a Fab fragment.
- 37. An antibody-drug conjugate compound selected from the structures:
-
44. A mixture of antibody-drug conjugate compounds comprising a cysteine engineered anti-MUC16 antibody (Ab) which binds to a MUC16 polypeptide and comprising one or more free cysteine amino acids, a sequence selected from SEQ ID NOS:
- 9-40, and an auristatin drug moiety (D) wherein the cysteine engineered anti-MUC16 antibody is attached through one or more free cysteine amino acids by a linker moiety (L) to D;
the compound having Formula I;
Ab-(L-D)p
Iwhere p is 1, 2, 3, or 4, and the average drug loading is from 1 to 2.
- 9-40, and an auristatin drug moiety (D) wherein the cysteine engineered anti-MUC16 antibody is attached through one or more free cysteine amino acids by a linker moiety (L) to D;
-
45. A pharmaceutical formulation comprising an antibody-drug conjugate comprising a cysteine engineered anti-MUC16 antibody which binds to a MUC16 polypeptide and comprising one or more free cysteine amino acids and a sequence selected from SEQ ID NOS:
- 9-40 and where the cysteine engineered anti-MUC16 antibody is covalently attached to an auristatin drug moiety, and a pharmaceutically acceptable diluent, carrier or excipient.
- View Dependent Claims (46)
-
47. A method of treating cancer comprising administering to a patient a. pharmaceutical formulation comprising an antibody-drug conjugate comprising a cysteine engineered anti-MUC16 antibody which binds to a MUC16 polypeptide and having one or more free cysteine amino acids and a sequence selected from SEQ ID NOS:
- 9-40 and where the cysteine engineered anti-MUC16 antibody is covalently attached to an auristatin drug moiety, and a pharmaceutically acceptable diluent, carrier or excipient.
- View Dependent Claims (48, 49)
-
50. An article of manufacture comprising
a pharmaceutical formulation comprising an antibody-drug conjugate comprising a cysteine engineered anti-MUC16 antibody which binds to a MUC16 polypeptide and having one or more free cysteine amino acids and a sequence selected from SEQ ID NOS: - 9-40 and where the cysteine engineered anti-MUC16 antibody is covalently attached to an auristatin drug moiety, and a pharmaceutically acceptable diluent, carrier or excipient;
a container; and a package insert or label indicating that the compound can be used to treat cancer characterized by the overexpression of a MUC16 polypeptide. - View Dependent Claims (51)
- 9-40 and where the cysteine engineered anti-MUC16 antibody is covalently attached to an auristatin drug moiety, and a pharmaceutically acceptable diluent, carrier or excipient;
-
52. A method for making an antibody drug conjugate compound comprising a cysteine engineered anti-MUC16 antibody (Ab) which binds to a MUC16 polypeptide and having one or more free cysteine amino acids and a sequence selected from SEQ ID NOS:
- 9-40, and an auristatin drug moiety (D) wherein the cysteine engineered antibody is attached through the one or more engineered cysteine amino acids by a linker moiety (L) to D;
the compound having Formula I;
Ab-(L-D)p
Iwhere p is 1, 2, 3, or 4;
the method comprising the steps of;(a) reacting an engineered cysteine group of the cysteine engineered antibody with a linker reagent to form antibody-linker intermediate Ab-L; and (b) reacting Ab-L with an activated drug moiety D;
whereby the antibody-drug conjugate compound is formed;or comprising the steps of; (c) reacting a nucleophilic group of a drug moiety with a linker reagent to form drug-linker intermediate D-L; and (d) reacting D-L with an engineered cysteine group of the cysteine engineered antibody;
whereby the antibody-drug conjugate compound is formed. - View Dependent Claims (53, 54, 55, 56, 57)
- 9-40, and an auristatin drug moiety (D) wherein the cysteine engineered antibody is attached through the one or more engineered cysteine amino acids by a linker moiety (L) to D;
Specification